|
Virus Diseases
|
0.320 |
GeneticVariation
|
group |
BEFREE |
The SS risk allele of rs10774671 has been shown by others to be associated with reduced OAS1 enzymatic activity and ability to clear viral infections, as well as reduced responsiveness to IFN treatment.
|
28640813 |
2017 |
|
Virus Diseases
|
0.320 |
Biomarker
|
group |
BEFREE |
Although still preliminary, a few recent observations also substantiate a possible role for OAS1 in human susceptibility to viral infections (West Nile virus, SARS, etc.) and its possible involvement in some other diseases such as type 1 diabetes and multiple sclerosis.
|
18727488 |
2008 |
|
Virus Diseases
|
0.320 |
Biomarker
|
group |
CTD_human |
This genetic polymorphism makes OAS1 an excellent candidate for a human gene that influences host susceptibility to viral infection.
|
15732009 |
2005 |
|
Influenza
|
0.310 |
AlteredExpression
|
disease |
BEFREE |
Levels of virus along with IFN-β and IFN-λ and IFN-stimulated gene expression (tracked by 2'-5'-oligoadenylate synthetase 1 and myxovirus (influenza virus) resistance 1 mRNA) were determined up to 72 hours postinoculation.
|
25216987 |
2014 |
|
Influenza
|
0.310 |
Biomarker
|
disease |
CTD_human |
A host transcriptional signature for presymptomatic detection of infection in humans exposed to influenza H1N1 or H3N2.
|
23326326 |
2013 |
|
Pulmonary alveolar proteinosis, congenital
|
0.300 |
GermlineCausalMutation
|
disease |
ORPHANET |
Heterozygous Mutations in OAS1 Cause Infantile-Onset Pulmonary Alveolar Proteinosis with Hypogammaglobulinemia.
|
29455859 |
2018 |
|
Hepatitis, Toxic
|
0.200 |
Biomarker
|
disease |
CTD_mouse |
Blood gene expression signatures predict exposure levels.
|
17984051 |
2007 |
|
Drug-Induced Liver Disease
|
0.200 |
Biomarker
|
phenotype |
CTD_mouse |
Blood gene expression signatures predict exposure levels.
|
17984051 |
2007 |
|
Hepatitis, Drug-Induced
|
0.200 |
Biomarker
|
disease |
CTD_mouse |
Blood gene expression signatures predict exposure levels.
|
17984051 |
2007 |
|
Drug-Induced Acute Liver Injury
|
0.200 |
Biomarker
|
disease |
CTD_mouse |
Blood gene expression signatures predict exposure levels.
|
17984051 |
2007 |
|
Chemical and Drug Induced Liver Injury
|
0.200 |
Biomarker
|
disease |
CTD_mouse |
Blood gene expression signatures predict exposure levels.
|
17984051 |
2007 |
|
Chemically-Induced Liver Toxicity
|
0.200 |
Biomarker
|
disease |
CTD_mouse |
Blood gene expression signatures predict exposure levels.
|
17984051 |
2007 |
|
Diabetes Mellitus, Non-Insulin-Dependent
|
0.110 |
GeneticVariation
|
disease |
GWASDB |
New susceptibility loci in MYL2, C12orf51 and OAS1 associated with 1-h plasma glucose as predisposing risk factors for type 2 diabetes in the Korean population.
|
23575436 |
2013 |
|
Diabetes Mellitus, Non-Insulin-Dependent
|
0.110 |
GeneticVariation
|
disease |
BEFREE |
New susceptibility loci in MYL2, C12orf51 and OAS1 associated with 1-h plasma glucose as predisposing risk factors for type 2 diabetes in the Korean population.
|
23575436 |
2013 |
|
Diabetes Mellitus, Non-Insulin-Dependent
|
0.110 |
GeneticVariation
|
disease |
GWASCAT |
New susceptibility loci in MYL2, C12orf51 and OAS1 associated with 1-h plasma glucose as predisposing risk factors for type 2 diabetes in the Korean population.
|
23575436 |
2013 |
|
Uric acid measurement (procedure)
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
Target genes, variants, tissues and transcriptional pathways influencing human serum urate levels.
|
31578528 |
2019 |
|
Hepatitis C
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
MxA-mediated inhibition of HCV replication was found to involve the JAK-STAT pathway: STAT1 phosphorylation and the expression of IFN-stimulated genes (ISGs) such as guanylate-binding protein 1 and 2'-5'-oligoadenylate synthetase 1 were augmented by MxA overexpression and reduced by endogenous MxA silencing.
|
29417241 |
2018 |
|
Blood Protein Measurement
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
Genomic atlas of the human plasma proteome.
|
29875488 |
2018 |
|
Blood Protein Measurement
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
Co-regulatory networks of human serum proteins link genetics to disease.
|
30072576 |
2018 |
|
Hepatitis C
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
In conclusion, Mx1 and OAS1-2 polymorphisms were associated with the severity of liver disease in HIV/HCV-coinfected patients, suggesting a significant role in the progression of hepatic fibrosis.
|
28139728 |
2017 |
|
Hepatitis C
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The polymorphism at OAS1 exon 7 rs3741981 might be a potential genetic marker and can be useful in the assessment of liver fibrosis progression and disease outcome in HCV-infected patients.
|
26505957 |
2015 |
|
Hepatitis C
|
0.100 |
Biomarker
|
disease |
BEFREE |
Therefore, in this study, gene expression of human immune responsive genes (MMP-9, OAS1) and fibrogenic responsive gene (KRT19) was done in the peripheral blood mononuclear cells (PBMCs) of chronic HCV infected patients having differences in viral titers.
|
24811215 |
2014 |
|
Hepatitis C
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Investigation of the mechanisms showed that HCV infection suppressed the expression of poly I:C-induced IFN-λ1 and IFN-stimulated genes [IFN-stimulated gene 56 (ISG-56), myxovirus resistance A (MxA) and 2'-5'-oligoadenylate synthetase 1 (OAS-1))], the key antiviral elements in IFN signaling pathway.
|
23529855 |
2014 |
|
Hepatitis C
|
0.100 |
Biomarker
|
disease |
BEFREE |
The aim of this study was to investigate the role of single nucleotide polymorphism (SNP) at the exon 7 splice acceptor site (SAS) of OAS1 to interferon-based therapy of HCV infection.
|
24673406 |
2014 |
|
Hepatitis C
|
0.100 |
Biomarker
|
disease |
BEFREE |
Our data suggested that among the members of the OAS family, OAS1 p46 and OAS3 p100 mediate the RNase L-dependent antiviral activity against HCV.
|
23196181 |
2013 |